Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Lyell Immunopharma Inc (LYEL)
Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 501,714
  • Shares Outstanding, K 249,609
  • Annual Sales, $ 84,680 K
  • Annual Income, $ -183,120 K
  • 60-Month Beta -1.68
  • Price/Sales 5.98
  • Price/Cash Flow N/A
  • Price/Book 0.61
Trade LYEL with:

Options Overview Details

View History
  • Implied Volatility 92.70% ( -71.17%)
  • Historical Volatility 77.41%
  • IV Percentile 57%
  • IV Rank 30.94%
  • IV High 294.14% on 02/14/23
  • IV Low 2.46% on 06/06/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 184
  • Open Int (30-Day) 187

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.31
  • Prior Year -0.28
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.83 +9.97%
on 03/23/23
2.48 -18.95%
on 03/01/23
-0.12 (-5.63%)
since 02/24/23
3-Month
1.83 +9.97%
on 03/23/23
3.61 -44.32%
on 01/04/23
-1.04 (-34.10%)
since 12/23/22
52-Week
1.83 +9.97%
on 03/23/23
8.74 -77.00%
on 09/12/22
-3.11 (-60.74%)
since 03/24/22

Most Recent Stories

More News
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

LYEL : 2.01 (-0.99%)
LYRA : 1.9500 (-2.74%)
Lyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...

LYEL : 2.01 (-0.99%)
Lyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 17.65% and 99.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LYEL : 2.01 (-0.99%)
AFIB : 0.7810 (-3.56%)
Assertio (ASRT) Q3 Earnings and Revenues Top Estimates

Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ASRT : 5.86 (+1.21%)
LYEL : 2.01 (-0.99%)
Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?

Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LYEL : 2.01 (-0.99%)
XERS : 1.2800 (unch)
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0% and 11.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

DRRX : 4.40 (-2.87%)
LYEL : 2.01 (-0.99%)
Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates

Catalent (CTLT) delivered earnings and revenue surprises of -38.18% and 4.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CTLT : 64.27 (+2.60%)
LYEL : 2.01 (-0.99%)
Is Catalyst Pharmaceuticals (CPRX) Outperforming Other Medical Stocks This Year?

Here is how Catalyst Pharmaceutical (CPRX) and Lyell Immunopharma (LYEL) have performed compared to their sector so far this year.

CPRX : 16.12 (+0.62%)
LYEL : 2.01 (-0.99%)
Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 91%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 91% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the...

LYEL : 2.01 (-0.99%)
Lyell Immunopharma (LYEL) Reports Q2 Loss, Tops Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 51.61% and 960.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LYEL : 2.01 (-0.99%)
KMPH : 5.81 (-0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 2.12
2nd Resistance Point 2.08
1st Resistance Point 2.04
Last Price 2.01
1st Support Level 1.96
2nd Support Level 1.92
3rd Support Level 1.88

See More

52-Week High 8.74
Fibonacci 61.8% 6.10
Fibonacci 50% 5.28
Fibonacci 38.2% 4.47
Last Price 2.01
52-Week Low 1.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar